Top Markets
Coin of the day
Hansa Biopharma AB (publ) Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ)

HNSA
株式のランク #13465
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing... Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
株価
$4.87
時価総額
$485.24M
変化(1日)
-2.20%
変化(1年)
42.26%
SE
取引 Hansa Biopharma AB (publ) (HNSA)

カテゴリー

Hansa Biopharma AB (publ)(HNSA)の株価履歴
終値の最高値: $4.66 (2026-08-01)

終値の最安値: $1.23 (2007-10-01)
Hansa Biopharma AB (publ) の株価履歴(2007 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) 3.22%
2025 18.06%
2024 24.12%
2023 -52.92%
2022 -47.02%
2021 -65.69%
2020 170.40%
2019 -67.23%
2018 9.70%
2017 122.57%
2016 324.99%
2015 -11.09%
2014 181.45%
2013 131.04%
2012 -16.18%
2011 22.26%
2010 -23.87%
2009 62.04%
2008 -57.53%
2007 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$538.60 37.74%
US
$1.02K 43.09%
NL
$121.01 -13.08%
AU
$141.48 487.28%
US
$751.98 6.17%
CH